2026-10-06

Two probiotic products can list the exact same organism, the same Colony-Forming Unit (CFU) count, and still work completely differently once they reach the gut. One strain might survive digestion and settle in the intestine well. Another, carrying the identical species name, might not make it that far at all. That difference used to go unnoticed. Now, it's the question the entire industry is being asked to answer.

Take Bacillus coagulans as an example. Two strains of this same species do not behave the same way inside the body. Two strains of the same species can differ in spore germination, acid and bile tolerance, and the metabolites they produce—differences that decide whether a strain survives transit and acts at all. A clinical result proven for one strain cannot be assumed to apply to another that happens to share its name.

Taxonomy has caught up with this understanding. In 2020, researchers split the Lactobacillus genus, once home to over 250 species, into 25 distinct genera using whole-genome sequencing and core genome phylogeny. Familiar organisms were reassigned to genera such as Lacticaseibacillus, Lactiplantibacillus and Limosilactobacillus.

The International Scientific Association for Probiotics and Prebiotics (ISAPP) and the World Gastroenterology Organisation have both been direct about what this means in practice. Probiotic effects are strain-specific and dose-specific, and pooling data across strains without a shared, demonstrated mechanism is no longer considered sound science.

This precision now extends to how efficacy itself gets evaluated. A product labelled simply Lacticaseibacillus rhamnosus is not making the same claim as one that names Lacticaseibacillus rhamnosus GG specifically.

The clinical record behind GG, including its role in reinforcing gut barrier function and immune signalling, belongs to that exact, deposited strain. A different, uncharacterised L. rhamnosus culture carries the same species name but not the same evidence. The same logic shows up in trial data.

A 2025 network meta-analysis of 16 randomised trials in pediatric patients found that Lacticaseibacillus rhamnosus GG was the most effective strain studied for improving SCORAD severity scores and quality of life, while a different named strain, Lactobacillus acidophilus LB, performed better specifically at reducing IgE levels. Neither result transfers automatically to an unnamed product carrying either species name. The strain identity is the finding, not the species it belongs to. Grouping such organisms under one umbrella claim erases the exact information that makes a claim credible in the first place.

Consumer interest in probiotics generally has grown alongside this shift. A global survey of more than 13,000 respondents across 16 countries recorded awareness of probiotics and cultures climbing from 42 percent in 2019 to 47 percent 2 years later. That reflects category-level interest rather than evidence that shoppers are reading strain names on a label, but it does show a market more receptive than ever to claims grounded in specifics rather than broad wellness language.

This same shift toward precision is what is driving the next generation of probiotics.

Organisms such as Akkermansia muciniphila and Faecalibacterium prausnitzii, both isolated from within the human gut microbiome itself rather than from conventional fermented sources, represent this new category.

A. muciniphila's pasteurised form was cleared by the European Commission (EC) as a Novel Food in 2022, while F. prausnitzii remains largely in investigational and live biotherapeutic development. Both illustrate where the field is heading, toward organisms selected and validated for a specific, demonstrated function rather than a broad, familiar species name.

Finding and validating organisms like these depends on tools that did not exist a decade ago. Metagenomics and whole-genome sequencing let researchers work from function back to organism, rather than screening cultures one at a time. Machine Learning (ML) is compressing this further. Platforms can now screen candidate strains directly from genomic sequences, identifying probiotic-associated features with prediction accuracy above 97 percent in published models, and predict traits such as acid resistance, bile tolerance and adhesion before a strain ever reaches a wet-lab trial. None of this replaces clinical validation, but it is dramatically shortening the distance between discovering a promising organism and being able to properly study it.

Regulation is moving to keep pace with this shift. India's framework already draws probiotic strains from an approved list, requires packaging to declare genus, species and strain rather than a generic category, and mandates a minimum viable count through the product's stated shelf life.

In the European Union (EU), organisms without an established history of human consumption must clear the novel food authorisation route before reaching the market, and health claims face close scrutiny for strain-specific evidence.

In the US, live biotherapeutic products intended to treat disease are regulated as biologics, separately and more strictly than conventional dietary-supplement probiotics. The direction across these frameworks is the same: claims need to be tied to a specific, evidenced strain, not a category.

India is positioning itself to compete on these terms. The government's BioE3 Policy, approved by the Union Cabinet in August 2024, is actively expanding the country's fermentation and biomanufacturing infrastructure to support this kind of precision-led, science-first production.

The global probiotics market is projected to reach roughly USD 220 billion by 2030, and the strength of a formulation within that market will depend increasingly on how thoroughly each strain in it has been studied.